News

Sara F. Grace, MD, discussed medications and diseases that dermatologists encounter in treating patients.

Carrie Coughlin, MD, discussed how dermatologists can gain insight into their patient’s preferences using qualitative research tools.

Peter Lio, MD also explained why he considers it a bad day when he does not learn something new about this disease.

Jemima Mellerio, MD, covered recent developments for managing epidermolysis bullosa and the challenges of studying rare diseases.

Jane Bellet, MD, will present 2 sessions full of pearls to ensure tiny fingers and toes are cared for in a timely, heartfelt, and effective treatment regimen.

A multicenter study to further explore treatment of kaposiform hemangioendotheliomas has been proposed after untreated patients did not develop Kasabach Merritt Phenomenon.

Bree will discuss the organization she founded and how it helps children with skin diseases and birthmarks.

AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component.

During pregnancy and lactation, physiological changes occur in the body that can impact the development and management of acne.

Steve Feldman, MD, PhD, is part of an atopic dermatitis panel and focuses on strategies to hold pediatric patients and their parents accountable to treatment methods.

Zoe Diana Draelos, MD, reviews the importance of expanding societal and cosmetic ideas of beauty to be reflective of all skin types, ages, and more.

Coverage for eligible patients began July 12, 2023.

Summer months bring time outside. With July being UV Awareness month, we are highlighting some past articles you may have missed.

Real-world data demonstrated marked impacts on the economy on a national and personal level.

Nurse practitioners and physician assistants play a crucial role in dermatology, and Dermatology Times is proud to curate content embracing and empowering the NP/PA community.

IL-17A was antagonized by secukinumab, while several other serum levels were decreased in expression.

Answer today's poll below.

Course directors share which pearls, sessions, and insights they are looking forward to this weekend in Asheville, North Carolina.

When sessions conclude, you will find no shortage of opportunities to keep you busy.

A study found that the costs associated with managing comorbidities of hidradenitis suppurativa increase among adults and adolescents.

In this week’s Pointers With Portela, the 208SkinDoc answers frequently asked questions about retinol use.

The American Skin Association estimated that 50 million Americans are exposed to urushiol yearly, the most common contact allergen in the US.

Patients with the rare autosomal recessive genodermatosis are prone to extreme photosensitivity and changes in skin pigmentation.

Additional patients will be enrolled in the phase 2a study after a clear biological signal was demonstrated in initial participants.

The TRuE-AD3 study met its primary endpoint of IGA-TS improvement from baseline at week 8.

Based on the positive topline phase 3 results, Journey Medical plans to submit a New Drug Application to the FDA in the second half of 2023.

Incyte representative Todd Edwards discusses how the awards help address challenges faced by patients with vitiligo.

Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon.

Researchers sought to challenge the perception of microneedling as disruptive to the skin and disease states.

Researchers conducted a review of treatments for the rare disease in the pediatric population.